Cocaine and kappa-opioid withdrawal in Planaria blocked by D-, but not L-, glucose

Brain Res. 2004 Aug 27;1018(2):181-5. doi: 10.1016/j.brainres.2004.05.057.

Abstract

Planarians (Dugesia dorotocephala) that were exposed for 1 h to cocaine (80 microM) or to the kappa-selective opioid receptor agonist U-50,488H (1 microM) displayed an abstinence-induced withdrawal syndrome, indicative of the development of physical dependence, when they were tested in cocaine- (or U-50,488H-) free water, but not when they were tested in cocaine- (or U-50,488H-) containing water. The withdrawal was manifested as a significant (P<0.05) decrease in the rate of planarian spontaneous locomotor activity over a 5-min observation period, using a recently designed metric. Co-exposure of the planarians to D-glucose (1 microM) or to 2-deoxy-D-glucose (2-DG, 1 microM), but not to L-glucose (1 microM), significantly attenuated (P<0.05) the development of physical dependence, shown by an attenuated withdrawal syndrome, from cocaine and U-50,488H. These results suggest that either D-glucose and 2-deoxy-D-glucose compete with a common cocaine and kappa-opioid transport mechanism or that the development of physical dependence (or the inhibition of abstinence-induced withdrawal) in planarians requires energy supplied from glucose metabolism.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / pharmacology*
  • Adaptation, Physiological
  • Animals
  • Behavior, Addictive / metabolism
  • Behavior, Addictive / physiopathology
  • Carbohydrate Conformation
  • Cocaine / pharmacology*
  • Disease Models, Animal
  • Glucose / chemistry*
  • Glucose / metabolism*
  • Narcotic Antagonists / pharmacology
  • Opioid-Related Disorders / metabolism
  • Opioid-Related Disorders / physiopathology
  • Planarians / drug effects*
  • Planarians / metabolism
  • Receptors, Opioid, kappa / antagonists & inhibitors*
  • Substance Withdrawal Syndrome / metabolism*
  • Substance Withdrawal Syndrome / physiopathology

Substances

  • Narcotic Antagonists
  • Receptors, Opioid, kappa
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • Cocaine
  • Glucose